These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2030884)

  • 1. The FDA's new drug rating system.
    Ohio Med; 1991 Mar; 87(3):133-4. PubMed ID: 2030884
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA's classification of new drugs.
    Schneiweiss F
    N Engl J Med; 1980 Jun; 302(24):1368-9. PubMed ID: 7374693
    [No Abstract]   [Full Text] [Related]  

  • 3. Understanding the FDA's guarded system for classifying new drugs.
    Schneiweiss F
    Hosp Pharm; 1979 May; 14(5):262-4, 266, 268 passim. PubMed ID: 10316828
    [No Abstract]   [Full Text] [Related]  

  • 4. The FDA's classification system for new drugs. An evaluation of therapeutic gain.
    Finkel MJ
    N Engl J Med; 1980 Jan; 302(3):181-3. PubMed ID: 7350458
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's biomedical research program.
    Kelsey FO
    J Parenter Drug Assoc; 1980; 34(2):134-8. PubMed ID: 6989974
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach.
    Kuhlik BN
    Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA's response to AIDS: paradigm shift in new drug policy?
    Podraza R
    Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA's Bioresearch Monitoring Program.
    Kelsey FO
    Methods Find Exp Clin Pharmacol; 1982; 4(7):503-8. PubMed ID: 7169836
    [No Abstract]   [Full Text] [Related]  

  • 11. PDA's response to FDA's "Guideline on sterile drug products produced by aseptic processing".
    Akers JE; Agalloco JP; Carleton FJ; Korczynski MS
    J Parenter Sci Technol; 1988; 42(4):114-7. PubMed ID: 3183865
    [No Abstract]   [Full Text] [Related]  

  • 12. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

  • 13. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.
    Poirier TI; Vorbach M; Bache T
    Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA's implementation of FDAMA: an interim balance sheet.
    Suydam LA; Kubic MJ
    Food Drug Law J; 2001; 56(2):131-5. PubMed ID: 12022190
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA's FDAMA accomplishments--one year after enactment.
    Ann Pharmacother; 1999 Jan; 33(1):134. PubMed ID: 9972401
    [No Abstract]   [Full Text] [Related]  

  • 17. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA Export Reform and Enhancement Act of 1996: the FDA's new extraterritorial authority over labeling and promotional practices.
    Helmanis AM
    Food Drug Law J; 1996; 51(4):631-5. PubMed ID: 11797732
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's position on the clozaril patient management system.
    Peck CC
    Hosp Community Psychiatry; 1990 Aug; 41(8):876-7. PubMed ID: 2401475
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA's safety reform is greeted with scepticism.
    Moynihan R
    BMJ; 2005 Feb; 330(7489):435. PubMed ID: 15731128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.